MYOCARDIAL ISCHEMIA Cooperative mediation by serotonin S 2 and thromboxane A 2 / prostaglandin H 2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses
J. Ashton,M. Ogletree,I. Michel,P. Golino,J. McNatt,Anne L. Taylor,S. Raheja,J. Schmitz,L. Buja,W. Campbell,J. Willerson
Abstract:We have reported previously that thromboxane A2/prostaglandin (PG)H2 and serotonin independently mediate the occurrence of cyclic flow variations (CFVs) in a canine preparation of severe coronary artery narrowing. This may be due to an effect of these substances on platelets and/or the vascular wall. We tested the hypothesis that there is a cooperative effect between thromboxane A2/PGH2 and serotonin receptor stimulation in the development of CFVs in this animal preparation. After placement of a hard plastic cylindrical constrictor around the left anterior descending coronary artery, CFVs develop and are characterized by repetitive cycles of declines in coronary blood flow and abrupt increases in flow. In a control group of dogs, CFV frequency (cycles/hour) and severity (lowest coronary blood flow just before its restoration) did not change significantly over a 3 hr interval. In a second group of dogs, CFVs were established after constrictor placement, abolished with the serotonin (5HT2) receptor antagonist ketanserin, and reestablished by the continuous infusion of serotonin into the left atrium. Serotonin-induced CFVs were then abolished with a thromboxane A2/PGH2 receptor antagonist, SQ29,548, or a thromboxane synthetase inhibitor, dazoxiben (UK37,248). The relative specificity of the respective antagonists, SQ29,548 and ketanserin, was determined in canine platelets and rat aortic vascular strips. No significant cross-reactivity between ketanserin and SQ29,548 was found. Thus, the data obtained in these studies demonstrate a cooperative interaction between thromboxane A2/PGH2 and serotonin S2 receptors that contributes to the development of CFVs in this experimental preparation. Circulation 76, No. 4, 952-959, 1987. THE NATURE OF the interaction between platelets and the vascular wall is altered by the presence of atherosclerosis and coronary artery narrowing.' Transient platelet aggregation and subsequent release of platelet contents in damaged and atherosclerotic coronary arteries may be important in the pathogenesis of selected coronary artery disease syndromes such as unstable angina and acute myocardial infarction.23 Data reported from our laboratory have demonFrom the Departments of Intemal Medicine (Cardiology Division), Pharmacology and Pathology at the University of Texas Health Science Center at Dallas, and the Department of Pharmacology at the Squibb Institute for Medical Research. Princeton, NJ. Supported in part by NHLBI Ischemic SCOR grant HL 17669, HL 25471, HL 34837, and the Moss Heart Fund, Dallas. Address for correspondence: Juliet Ashton, Ph.D., Cardiology Division/Room L5. 134, University of Texas Health Science Center, 5323 Harry Hines Blvd., Dallas, TX 75235-9047. Received July 1 1, 1986; revision accepted June 18, 1987. 952 strated that thromboxane A2 and occupation of the platelet and/or vascular thromboxane A2/prostaglandin (PG)H2 receptors are important in mediating transient blood flow reductions in narrowed canine coronary arteries.6 Both thromboxane6 and serotonin7 concentrations are increased at the site of severe canine coronary artery narrowing. We reported that thromboxane synthetase inhibition with dazoxiben (UK-37,248, Pfizer)4 or selective thromboxane A2/PGH2 receptor antagonism with SQ29,548 or SQ28,668 (Squibb)5 eliminates the transient flow reductions in narrowed canine coronary arteries in approximately 70% of the animals. Moreover, a serotonin .2 (5HT2) receptor antagonist, ketanserin (R41,468), abolishes transient blood flow reductions in stenosed coronary arteries in over 90% of dogs tested.8 Once platelets are activated by subendothelial collagen and undergo the release action, multiple mediCIRCULATION by gest on Sptem er 2, 2017 http://ciajournals.org/ D ow nladed from LABORATORY INVESTIGATION-MxYOCARDIAL ISCHEMIA ators are available to other platelets in vivo. Many of these mediators are known to act synergistically, at least in vitro, to augment the overall platelet response and ultimately result in irreversible aggregation of the activated platelets.9 The present study was designed to test the hypothesis that stimulation of both thromboxane A2/PGH2 and 5HT2 receptors on platelets and/or within the coronary vascular wall interact cooperatively in leading to the development of transient flow reductions in a canine preparation of severe coronary